Clinical Trial

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Name: Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC — clinical trial record (NCT05009836)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SANOVO

Active, Not Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer

Trial Details

NCT Number	NCT05009836
Lead Sponsor	Hutchison Medipharma Limited
Conditions	Non-small Cell Lung Cancer
Enrollment	412 participants
Start Date	2021-09-06
Primary Completion	2028-05-30 (estimated)
Study Completion	2028-05-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-10